ภาษาไทย
English
SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson Sonsini and the BayHelix Group, recognized outstanding achievements in healthcare investment, financing, and deal-making over the past year.
This year's awards honored the companies and individuals at the forefront of China's dynamic healthcare sector — from landmark licensing and partnership agreements to capital markets milestones and private financings that are reshaping the industry. Award recipients were selected through a formal vote conducted by CHIC's Founders and 2026 Organizing Committee & Working Group, whose collective expertise spans venture capital, private equity, and global healthcare leadership.
Award Winners
IPO of the Year
Winner: Insilico Medicine
Accepted by: Leah Liu, VP and Global Head of IR & Capital Markets, Insilico Medicine
Presenter: Richard Wang, China Partner, Wilson Sonsini
Private Financing of the Year — Tied
Co-Winner: Kailera Therapeutics
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui (Kailera Therapeutics was built on Hengrui assets)
Presenter: Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Co-Winner: Vor Bio
Accepted by: Jianmin Fang, CEO, RemeGen (Vor Bio's leading project is from RemeGen)
Presenter: Cyber Cao, Managing Director, HSG
Deal of the Year — Tied
Co-Winner: Hengrui Pharma – GSK
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui; and Ming Fang, PhD, Senior Director, Search & Evaluation, Business Development, GSK
Presenter: Steve Yang, Co-Founder, the BayHelix Group; Co-CEO, WuXi Apptec
Co-Winner: Innovent – Takeda
Accepted by: Sophy Wang, Board Secretary & Global BD, Innovent; and Eric Yeung, Head of Oncology and Global Business Development, Takeda
Presenter: Kevin Yuan, CEO, Hankang Capital
About CHIC 2026
The China Healthcare Investment Conference (CHIC) is a premier platform connecting innovation and investment in China's healthcare sector. Now in its 12th year, CHIC brings together senior decision-makers including venture capital and private equity investors, pharmaceutical executives, and biotech and medtech CEOs. The 2026 conference was held on March 23–24 at The Ritz-Carlton Hotel Pudong, Shanghai, under the theme "Innovation in Healthcare – The Answer to Uncertainty."
About the Gala Dinner Co-Hosts
Wilson Sonsini is a leading legal advisor to life sciences, and biotechnology industries, offering integrated counsel across the full spectrum of a company's life cycle — from early-stage intellectual property strategy and patent prosecution to complex technology transactions, licensing, collaborations, as well as M&As, IPOs and capital market offerings. As Founding Platinum Sponsor of CHIC, Wilson Sonsini has been a steadfast partner in the conference's mission to connect healthcare innovation with global capital.
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix serves as a co-host of the CHIC Gala Dinner and is a longstanding partner in advancing the global development of China's healthcare sector.
CHIC 2026 Founding Individuals & Organizing Committee / Working Group
The following individuals served as the voting body for the CHIC 2026 Awards, representing the CHIC Founding Individuals and the Organizing Committee & Working Group.
Founders
Marietta Wu, Managing Director, Quan Capital
Frank Kung, Managing Partner, Vivo Capital
Hongbo Lu, Managing Member, NEXTBio Capital
James Li, Venture Partner, Frazier Lifesciences
Norman Chen, CEO, The Asian American Foundation
2026 Organizing Committee & Working Group
Cyber Cao, Managing Director, HSG
Jialing Dai, President & Publisher, PharmaDJ
Tess Cameron, Managing Director, RA Capital Management
Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Sean Zhang, Executive Director, Vivo Capital
Dandan Dong, Venture Partner, TCGX
Anna Chen, Partner, Frazier Life Sciences
Yuan Yuan, Head of Platform Development, China, NEXTBio Capita
Zhanghang Yan, Vice President, Quan Capital
Yun Gao, Principal, Lilly Asia Ventures
Comment